2016 Fiscal Year Final Research Report
The CD44v9-targeted therapy for intractable ovarian cancer
Project/Area Number |
26462533
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Obstetrics and gynecology
|
Research Institution | Nara Medical University |
Principal Investigator |
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Keywords | 癌幹細胞マーカー / 卵巣がん分子マーカー / 明細胞癌治療 / スルファサラジン |
Outline of Final Research Achievements |
The endometriotic epithelial cells of benign OE (ovarian endometrioma) and endometriotic lesions adjacent to clear cell carcinoma tumorous tissue (CCC endometriotic tissues) were immunostained for CD44v9 and 8-OHdG. In CCC endometriotic tissues, CD44v9 expression was downregulated, and 8-OHdG was upregulated compared to benign OE. And a significant negative correlation between CD44v9 and 8-OHdG expression was identified. Alterations in CD44v9 and 8-OHdG may be associated with malignant transformation of benign OE. In the CCC cell line which expressed CD44v9, the xCT inihibitor sulfasalazine with anticancer agents had inhibited the cell growth. The combination chemotherapy with xCT inhibitor may become an effective therapy for CCC.
|
Free Research Field |
婦人科腫瘍学
|